Citi on Amylyx Pharmaceuticals inc. (AMLX): 'we think avexitide is well positioned to demonstrate success'
Tweet Send to a Friend
Citi analyst Geoff Meacham reiterated a Buy rating and $12.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
